Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1987 Aug 1;295(6593):288–290. doi: 10.1136/bmj.295.6593.288

Somatostatin.

S R Bloom 1, J M Polak 1
PMCID: PMC1247137  PMID: 2888511

Full text

PDF
288

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberti K. G., Christensen N. J., Christensen S. E., Hansen A. P., Iversen J., Lundbaek K., Seyer-Hansen K., Orskov H. Inhibition of insulin secretion by somatostatin. Lancet. 1973 Dec 8;2(7841):1299–1301. doi: 10.1016/s0140-6736(73)92873-0. [DOI] [PubMed] [Google Scholar]
  2. Alford F. P., Bloom S. R., Nabarro J. D., Hall R., Besser G. M., Coy D. H., Kastin A. J., Schally A. V. Glucagon control of fasting glucose in man. Lancet. 1974 Oct 26;2(7887):974–977. doi: 10.1016/s0140-6736(74)92071-6. [DOI] [PubMed] [Google Scholar]
  3. Arimura A., Sato H., Dupont A., Nishi N., Schally A. V. Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas. Science. 1975 Sep 19;189(4207):1007–1009. doi: 10.1126/science.56779. [DOI] [PubMed] [Google Scholar]
  4. Beal M. F., Mazurek M. F., Tran V. T., Chattha G., Bird E. D., Martin J. B. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. Science. 1985 Jul 19;229(4710):289–291. doi: 10.1126/science.2861661. [DOI] [PubMed] [Google Scholar]
  5. Beal M. F., Tran V. T., Mazurek M. F., Chattha G., Martin J. B. Somatostatin binding sites in human and monkey brain: localization and characterization. J Neurochem. 1986 Feb;46(2):359–365. doi: 10.1111/j.1471-4159.1986.tb12976.x. [DOI] [PubMed] [Google Scholar]
  6. Benoit R., Böhlen P., Brazeau P., Ling N., Guillemin R. Isolation and characterization of rat pancreatic somatostatin. Endocrinology. 1980 Dec;107(6):2127–2129. doi: 10.1210/endo-107-6-2127. [DOI] [PubMed] [Google Scholar]
  7. Bloom S. R., Mortimer C. H., Thorner M. O., Besser G. M., Hall R., Gomez-Pan A., Roy V. M., Russell R. C., Coy D. H., Kastin A. J. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet. 1974 Nov 9;2(7889):1106–1109. doi: 10.1016/s0140-6736(74)90869-1. [DOI] [PubMed] [Google Scholar]
  8. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973 Jan 5;179(4068):77–79. doi: 10.1126/science.179.4068.77. [DOI] [PubMed] [Google Scholar]
  9. Brown M. R. Central nervous system sites of action of bombesin and somatostatin to influence plasma epinephrine levels. Brain Res. 1983 Oct 16;276(2):253–257. doi: 10.1016/0006-8993(83)90732-1. [DOI] [PubMed] [Google Scholar]
  10. Brown M. R., Fisher L. A., Sawchenko P. E., Swanson L. W., Vale W. W. Biological effects of cysteamine: relationship to somatostatin depletion. Regul Pept. 1983 Jan;5(2):163–179. doi: 10.1016/0167-0115(83)90124-6. [DOI] [PubMed] [Google Scholar]
  11. Brown M. R., Rivier C., Vale W. Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. Endocrinology. 1984 May;114(5):1546–1549. doi: 10.1210/endo-114-5-1546. [DOI] [PubMed] [Google Scholar]
  12. Burhol P. G., Lygren I., Jenssen T. G., Florholmen J., Jorde R. Somatostatin release and plasma molecular somatostatin components in man. Acta Physiol Scand. 1984 Jul;121(3):223–228. doi: 10.1111/j.1748-1716.1984.tb07450.x. [DOI] [PubMed] [Google Scholar]
  13. Ch'ng J. L., Anderson J. V., Williams S. J., Carr D. H., Bloom S. R. Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue. Br Med J (Clin Res Ed) 1986 Apr 12;292(6526):981–982. doi: 10.1136/bmj.292.6526.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ch'ng L. J., Sandler L. M., Kraenzlin M. E., Burrin J. M., Joplin G. F., Bloom S. R. Long term treatment of acromegaly with a long acting analogue of somatostatin. Br Med J (Clin Res Ed) 1985 Jan 26;290(6464):284–285. doi: 10.1136/bmj.290.6464.284-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chanson P., Timsit J., Benoit O., Augendre B., Moulonguet M., Guillausseau P. G., Warnet A., Lubetzki J. Rapid improvement in sleep apnoea of acromegaly after short-term treatment with somatostatin analogue SMS 201-995. Lancet. 1986 May 31;1(8492):1270–1271. doi: 10.1016/s0140-6736(86)91405-4. [DOI] [PubMed] [Google Scholar]
  16. Christensen N. J., Hansen A. P., Lundbaek K. Metabolic and hormonal factors in diabetic retinopathy. Int Ophthalmol Clin. 1978 Winter;18(4):55–72. [PubMed] [Google Scholar]
  17. Christiansen J., Yotis A. The role of somatostatin and a long-acting analogue, SMS 201-995, in acute bleeding due to peptic ulceration. Scand J Gastroenterol Suppl. 1986;119:109–114. doi: 10.3109/00365528609087438. [DOI] [PubMed] [Google Scholar]
  18. Clements D., Elias E. Regression of metastatic vipoma with somatostatin analogue SMS 201-995. Lancet. 1985 Apr 13;1(8433):874–875. doi: 10.1016/s0140-6736(85)92235-4. [DOI] [PubMed] [Google Scholar]
  19. Colturi T. J., Unger R. H., Feldman M. Role of circulating somatostatin in regulation of gastric acid secretion, gastrin release, and islet cell function. Studies in healthy subjects and duodenal ulcer patients. J Clin Invest. 1984 Aug;74(2):417–423. doi: 10.1172/JCI111437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Colás B., Arilla E., Prieto J. C. Characterization of somatostatin binding sites in cytosolic fraction of pig retina. Neurosci Lett. 1986 Apr 11;65(2):193–198. doi: 10.1016/0304-3940(86)90303-4. [DOI] [PubMed] [Google Scholar]
  21. Daughaday W. H. A new treatment for an old disease. N Engl J Med. 1985 Dec 19;313(25):1604–1605. doi: 10.1056/NEJM198512193132509. [DOI] [PubMed] [Google Scholar]
  22. Davies P., Katzman R., Terry R. D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature. 1980 Nov 20;288(5788):279–280. doi: 10.1038/288279a0. [DOI] [PubMed] [Google Scholar]
  23. Draznin B., Sherman N., Sussman K., Dahl R., Vatter A. Internalization and cellular processing of somatostatin in primary culture of rat anterior pituitary cells. Endocrinology. 1985 Sep;117(3):960–966. doi: 10.1210/endo-117-3-960. [DOI] [PubMed] [Google Scholar]
  24. Elde R. P., Parsons J. A. Immunocytochemical localization of somatostatin in cell bodies of the rat hypothalamus. Am J Anat. 1975 Dec;144(4):541–548. doi: 10.1002/aja.1001440416. [DOI] [PubMed] [Google Scholar]
  25. Fine A. Peptides and Alzheimer's disease. Nature. 1986 Feb 13;319(6054):537–538. doi: 10.1038/319537a0. [DOI] [PubMed] [Google Scholar]
  26. Friesen S. R. Tumors of the endocrine pancreas. N Engl J Med. 1982 Mar 11;306(10):580–590. doi: 10.1056/NEJM198203113061005. [DOI] [PubMed] [Google Scholar]
  27. Fuessl H. S., Domin J., Bloom S. R. Oral absorption of the somatostatin analogue SMS 201-995: theoretical and practical implications. Clin Sci (Lond) 1987 Feb;72(2):255–257. doi: 10.1042/cs0720255. [DOI] [PubMed] [Google Scholar]
  28. Gerich J. E., Lorenzi M., Schneider V., Kwan C. W., Karam J. H., Guillemin R., Forsham P. H. Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin-dependent diabetics. Diabetes. 1974 Nov;23(11):876–880. doi: 10.2337/diab.23.11.876. [DOI] [PubMed] [Google Scholar]
  29. Gyr K., Kayasseh L., Stalder G. A., Prestèle H. Somatostatin: budget buster only, or effective anti-bleeding drug? Lancet. 1985 Jul 20;2(8447):155–156. doi: 10.1016/s0140-6736(85)90258-2. [DOI] [PubMed] [Google Scholar]
  30. Harrison P. J. Pathogenesis of Alzheimer's disease--beyond the cholinergic hypothesis: discussion paper. J R Soc Med. 1986 Jun;79(6):347–352. doi: 10.1177/014107688607900612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hoff G., Bjørneklett A., Moen I. E., Jenssen E. Epidemiology of polyps in the rectum and sigmoid colon. Evaluation of breath methane and predisposition for colorectal neoplasia. Scand J Gastroenterol. 1986 Mar;21(2):193–198. doi: 10.3109/00365528609034646. [DOI] [PubMed] [Google Scholar]
  32. Impicciatore M., Hansen D. G., Rachmilewitz D., Maitra S. K., Lugaro G., Grossman M. I. Comparison of human urine gastric inhibitor (HUGI) and bacterial endotoxin as inhibitors of acid secretion. Eur J Pharmacol. 1980 Aug 8;65(4):365–368. doi: 10.1016/0014-2999(80)90340-4. [DOI] [PubMed] [Google Scholar]
  33. Jenkins S. A., Baxter J. N., Corbett W. A., Shields R. Effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the pig and on intravariceal pressure in man. Br J Surg. 1985 Dec;72(12):1009–1012. doi: 10.1002/bjs.1800721225. [DOI] [PubMed] [Google Scholar]
  34. Kayasseh L., Gyr K., Keller U., Stalder G. A., Wall M. Somatostatin and cimetidine in peptic-ulcer haemorrhage. A randomised controlled trial. Lancet. 1980 Apr 19;1(8173):844–846. doi: 10.1016/s0140-6736(80)91352-5. [DOI] [PubMed] [Google Scholar]
  35. Keast J. R., Furness J. B., Costa M. Somatostatin in human enteric nerves. Distribution and characterization. Cell Tissue Res. 1984;237(2):299–308. doi: 10.1007/BF00217149. [DOI] [PubMed] [Google Scholar]
  36. Koch B. D., Schonbrunn A. The somatostatin receptor is directly coupled to adenylate cyclase in GH4C1 pituitary cell membranes. Endocrinology. 1984 May;114(5):1784–1790. doi: 10.1210/endo-114-5-1784. [DOI] [PubMed] [Google Scholar]
  37. Kraenzlin M. E., Ch'ng J. L., Wood S. M., Carr D. H., Bloom S. R. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology. 1985 Jan;88(1 Pt 1):185–187. doi: 10.1016/s0016-5085(85)80153-0. [DOI] [PubMed] [Google Scholar]
  38. Krukoff T. L., Ciriello J., Calaresu F. R. Somatostatin-like immunoreactivity in neurons, nerve terminals, and fibers of the cat spinal cord. J Comp Neurol. 1986 Jan 1;243(1):13–22. doi: 10.1002/cne.902430103. [DOI] [PubMed] [Google Scholar]
  39. Kuraishi Y., Hirota N., Sato Y., Hino Y., Satoh M., Takagi H. Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn. Brain Res. 1985 Jan 28;325(1-2):294–298. doi: 10.1016/0006-8993(85)90326-9. [DOI] [PubMed] [Google Scholar]
  40. Kvols L. K., Moertel C. G., O'Connell M. J., Schutt A. J., Rubin J., Hahn R. G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986 Sep 11;315(11):663–666. doi: 10.1056/NEJM198609113151102. [DOI] [PubMed] [Google Scholar]
  41. Lamberts S. W., Zweens M., Verschoor L., del Pozo E. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab. 1986 Jul;63(1):16–19. doi: 10.1210/jcem-63-1-16. [DOI] [PubMed] [Google Scholar]
  42. Langman M. J. Upper gastrointestinal bleeding: the trials of trials. Gut. 1985 Mar;26(3):217–220. doi: 10.1136/gut.26.3.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Long R. G., Christofides N. D., Fitzpatrick M. L., O'Shaughnessy D. J., Bloom S. R. Effects of intravenous somatostatin and motilin on the blood glucose and hormonal response to oral glucose. Eur J Clin Invest. 1982 Aug;12(4):331–336. doi: 10.1111/j.1365-2362.1982.tb02241.x. [DOI] [PubMed] [Google Scholar]
  44. Loud F. B., Holst J. J., Egense E., Petersen B., Christiansen J. Is somatostatin a humoral regulator of the endocrine pancreas and gastric acid secretion in man? Gut. 1985 May;26(5):445–449. doi: 10.1136/gut.26.5.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Lucey M. R. Endogenous somatostatin and the gut. Gut. 1986 Apr;27(4):457–467. doi: 10.1136/gut.27.4.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Lucey M. R. Endogenous somatostatin and the gut. Gut. 1986 Apr;27(4):457–467. doi: 10.1136/gut.27.4.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Lundqvist M., Wilander E. Somatostatin-like immunoreactivity in mid-gut carcinoids. Acta Pathol Microbiol Scand A. 1981 Jul;89(4):335–337. doi: 10.1111/j.1699-0463.1981.tb00229.x. [DOI] [PubMed] [Google Scholar]
  48. Magnusson I., Ihre T., Johansson C., Seligson U., Törngren S., Uvnäs-Moberg K. Randomised double blind trial of somatostatin in the treatment of massive upper gastrointestinal haemorrhage. Gut. 1985 Mar;26(3):221–226. doi: 10.1136/gut.26.3.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. McIntosh C., Bakich V., Trotter T., Kwok Y. N., Nishimura E., Pederson R., Brown J. Effect of cysteamine on secretion of gastrin and somatostatin from the rat stomach. Gastroenterology. 1984 May;86(5 Pt 1):834–838. [PubMed] [Google Scholar]
  50. Merkel C., Gatta A., Zuin R., Finucci G. F., Nosadini R., Ruol A. Effect of somatostatin on splanchnic hemodynamics in patients with liver cirrhosis and portal hypertension. Digestion. 1985;32(2):92–98. doi: 10.1159/000199224. [DOI] [PubMed] [Google Scholar]
  51. Mortimer C. H., Tunbridge W. M., Carr D., Yeomans L., Lind T., Coy D. H., Bloom S. R., Kastin A., Mallinson C. N., Besser G. M. Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet. 1974 Apr 20;1(7860):697–701. doi: 10.1016/s0140-6736(74)92903-1. [DOI] [PubMed] [Google Scholar]
  52. O'Shaughnessy D. J., Long R. G., Adrian T. E., Christofides N. D., Ghatei M. A., Sarson D. L., Bloom S. R. Somatostatin-14 modulates postprandial glucose levels and release of gastrointestinal and pancreatic hormones. Digestion. 1985;31(4):234–242. doi: 10.1159/000199205. [DOI] [PubMed] [Google Scholar]
  53. Osei K., O'Dorisio T. M. Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones. Ann Intern Med. 1985 Aug;103(2):223–225. doi: 10.7326/0003-4819-103-2-223. [DOI] [PubMed] [Google Scholar]
  54. Patel Y. C., Reichlin S. Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat. Endocrinology. 1978 Feb;102(2):523–530. doi: 10.1210/endo-102-2-523. [DOI] [PubMed] [Google Scholar]
  55. Pipeleers D., Couturier E., Gepts W., Reynders J., Somers G. Five cases of somatostatinoma: clinical heterogeneity and diagnostic usefulness of basal and tolbutamide-induced hypersomatostatinemia. J Clin Endocrinol Metab. 1983 Jun;56(6):1236–1242. doi: 10.1210/jcem-56-6-1236. [DOI] [PubMed] [Google Scholar]
  56. Plewe G., Nölken G., Krause U., del Pozo E., Beyer J. Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration. Scand J Gastroenterol Suppl. 1986;119:166–169. doi: 10.3109/00365528609087446. [DOI] [PubMed] [Google Scholar]
  57. Plotsky P. M., Vale W. Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat. Science. 1985 Oct 25;230(4724):461–463. doi: 10.1126/science.2864742. [DOI] [PubMed] [Google Scholar]
  58. Polak J. M., Bloom S. R. Somatostatin localization in tissues. Scand J Gastroenterol Suppl. 1986;119:11–21. doi: 10.3109/00365528609087427. [DOI] [PubMed] [Google Scholar]
  59. Polak J. M., Bloom S. R. Somatostatin localization in tissues. Scand J Gastroenterol Suppl. 1986;119:11–21. doi: 10.3109/00365528609087427. [DOI] [PubMed] [Google Scholar]
  60. Polak J. M., Pearse A. G., Grimelius L., Bloom S. R. Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells. Lancet. 1975 May 31;1(7918):1220–1222. doi: 10.1016/s0140-6736(75)92198-4. [DOI] [PubMed] [Google Scholar]
  61. Post R. M., Gold P., Rubinow D. R., Ballenger J. C., Bunney W. E., Jr, Goodwin F. K. Peptides in the cerebrospinal fluid of neuropsychiatric patients: an approach to central nervous system peptide function. Life Sci. 1982 Jul 5;31(1):1–15. doi: 10.1016/0024-3205(82)90394-0. [DOI] [PubMed] [Google Scholar]
  62. Price B. A., Jaffe B. M., Zinner M. J. Effect of exogenous somatostatin infusion on gastrointestinal blood flow and hormones in the conscious dog. Gastroenterology. 1985 Jan;88(1 Pt 1):80–85. doi: 10.1016/s0016-5085(85)80136-0. [DOI] [PubMed] [Google Scholar]
  63. Reichlin S. Somatostatin (second of two parts). N Engl J Med. 1983 Dec 22;309(25):1556–1563. doi: 10.1056/NEJM198312223092506. [DOI] [PubMed] [Google Scholar]
  64. Reichlin S. Somatostatin. N Engl J Med. 1983 Dec 15;309(24):1495–1501. doi: 10.1056/NEJM198312153092406. [DOI] [PubMed] [Google Scholar]
  65. Reisine T. Somatostatin desensitization: loss of the ability of somatostatin to inhibit cyclic AMP accumulation and adrenocorticotropin hormone release. J Pharmacol Exp Ther. 1984 Apr;229(1):14–20. [PubMed] [Google Scholar]
  66. Reubi J. C., Maurer R. Different ionic requirements for somatostatin receptor subpopulations in the brain. Regul Pept. 1986 Jul;14(4):301–311. doi: 10.1016/0167-0115(86)90172-2. [DOI] [PubMed] [Google Scholar]
  67. Reubi J. C., Maurer R., Klijn J. G., Stefanko S. Z., Foekens J. A., Blaauw G., Blankenstein M. A., Lamberts S. W. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab. 1986 Aug;63(2):433–438. doi: 10.1210/jcem-63-2-433. [DOI] [PubMed] [Google Scholar]
  68. Reubi J. C. New specific radioligand for one subpopulation of brain somatostatin receptors. Life Sci. 1985 May 13;36(19):1829–1836. doi: 10.1016/0024-3205(85)90155-9. [DOI] [PubMed] [Google Scholar]
  69. Roos B. A., Lindall A. W., Ells J., Elde R., Lambert P. W., Birnbaum R. S. Increased plasma and tumor somatostatin-like immunoreactivity in medullary thyroid carcinoma and small cell lung cancer. J Clin Endocrinol Metab. 1981 Feb;52(2):187–194. doi: 10.1210/jcem-52-2-187. [DOI] [PubMed] [Google Scholar]
  70. Samnegård H., Thulin L., Andreen M., Tydén G., Hallberg D., Efendić S. Circulatory effects of somatostatin in anaesthetized dogs. Acta Chir Scand. 1979;145(4):209–212. [PubMed] [Google Scholar]
  71. Schmidt M. I., Hadji-Georgopoulos A., Rendell M., Margolis S., Kowarski A. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care. 1981 Nov-Dec;4(6):579–585. doi: 10.2337/diacare.4.6.579. [DOI] [PubMed] [Google Scholar]
  72. Schusdziarra V., Lawecki J., Ditschuneit H. H., Lukas B., Maier V., Pfeiffer E. F. Effect of low-dose somatostatin infusion on pancreatic and gastric endocrine function in lean and obese nondiabetic human subjects. Diabetes. 1985 Jun;34(6):595–601. doi: 10.2337/diab.34.6.595. [DOI] [PubMed] [Google Scholar]
  73. Seiler M., Szabo S., Ourieff S., McComb D. J., Kovacs K., Reichlin S. The effect of the duodenal ulcerogen cysteamine on somatostatin and gastrin cells in the rat. Exp Mol Pathol. 1983 Oct;39(2):207–218. doi: 10.1016/0014-4800(83)90052-7. [DOI] [PubMed] [Google Scholar]
  74. Shepherd J. J., Senator G. B. Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995. Lancet. 1986 Sep 6;2(8506):574–574. doi: 10.1016/s0140-6736(86)90139-x. [DOI] [PubMed] [Google Scholar]
  75. Somerville K. W., Henry D. A., Davies J. G., Hine K. R., Hawkey C. J., Langman M. J. Somatostatin in treatment of haematemesis and melaena. Lancet. 1985 Jan 19;1(8421):130–132. doi: 10.1016/s0140-6736(85)91903-8. [DOI] [PubMed] [Google Scholar]
  76. Spiess J., Rivier J. E., Rodkey J. A., Bennett C. D., Vale W. Isolation and characterization of somatostatin from pigeon pancreas. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2974–2978. doi: 10.1073/pnas.76.6.2974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Spinas G. A., Bock A., Keller U. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus. Diabetes Care. 1985 Sep-Oct;8(5):429–435. doi: 10.2337/diacare.8.5.429. [DOI] [PubMed] [Google Scholar]
  78. Srikant C. B., Patel Y. C. Somatostatin receptors in the rat adrenal cortex: characterization and comparison with brain and pituitary receptors. Endocrinology. 1985 May;116(5):1717–1723. doi: 10.1210/endo-116-5-1717. [DOI] [PubMed] [Google Scholar]
  79. Srikant C. B., Patel Y. C. Somatostatin receptors on rat pancreatic acinar cells. Pharmacological and structural characterization and demonstration of down-regulation in streptozotocin diabetes. J Biol Chem. 1986 Jun 15;261(17):7690–7696. [PubMed] [Google Scholar]
  80. Stacpoole P. W., Kasselberg A. G., Berelowitz M., Chey W. Y. Somatostatinoma syndrome: does a clinical entity exist? Acta Endocrinol (Copenh) 1983 Jan;102(1):80–87. doi: 10.1530/acta.0.1020080. [DOI] [PubMed] [Google Scholar]
  81. Steiner C., Dahl R., Sherman N., Trowbridge M., Vatter A., Robbins R., Draznin B. Somatostatin receptors are biologically active before they are inserted into the plasma membrane. Endocrinology. 1986 Feb;118(2):766–772. doi: 10.1210/endo-118-2-766. [DOI] [PubMed] [Google Scholar]
  82. Szabo M., Berelowitz M., Pettengill O. S., Sorenson G. D., Frohman L. A. Ectopic production of somatostatin-like immuno- and bioactivity by cultured human pulmonary small cell carcinoma. J Clin Endocrinol Metab. 1980 Nov;51(5):978–987. doi: 10.1210/jcem-51-5-978. [DOI] [PubMed] [Google Scholar]
  83. Szabo S., Reichlin S. Somatostatin in rat tissues is depleted by cysteamine administration. Endocrinology. 1981 Dec;109(6):2255–2257. doi: 10.1210/endo-109-6-2255. [DOI] [PubMed] [Google Scholar]
  84. Tessler A., Himes B. T., Gruber-Bollinger J., Reichlin S. Characterization of forms of immunoreactive somatostatin in sensory neuron and normal and deafferented spinal cord. Brain Res. 1986 Apr 9;370(2):232–240. doi: 10.1016/0006-8993(86)90478-6. [DOI] [PubMed] [Google Scholar]
  85. Tran V. T., Beal M. F., Martin J. B. Two types of somatostatin receptors differentiated by cyclic somatostatin analogs. Science. 1985 Apr 26;228(4698):492–495. doi: 10.1126/science.2858917. [DOI] [PubMed] [Google Scholar]
  86. Tuchscherer M. M., Seybold V. S. Immunohistochemical studies of substance P, cholecystokinin-octapeptide and somatostatin in dorsal root ganglia of the rat. Neuroscience. 1985 Feb;14(2):593–605. doi: 10.1016/0306-4522(85)90313-6. [DOI] [PubMed] [Google Scholar]
  87. Webb S. M., Wass J. A., Penman E., Murphy M., Serrano J., Binimelis J., Pavía C. Circulating immunoreactive somatostatin in man. Effect of age, pregnancy, growth hormone deficiency and achlorhydria. Acta Endocrinol (Copenh) 1985 Oct;110(2):145–151. doi: 10.1530/acta.0.1100145. [DOI] [PubMed] [Google Scholar]
  88. Wiesenfeld-Hallin Z. Substance P and somatostatin modulate spinal cord excitability via physiologically different sensory pathways. Brain Res. 1986 Apr 30;372(1):172–175. doi: 10.1016/0006-8993(86)91473-3. [DOI] [PubMed] [Google Scholar]
  89. Williams G., Ball J. A., Burrin J. M., Joplin G. F., Bloom S. R. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995. Lancet. 1986 Oct 4;2(8510):774–778. doi: 10.1016/s0140-6736(86)90300-4. [DOI] [PubMed] [Google Scholar]
  90. Williams N. S., Cooper J. C., Axon A. T., King R. F., Barker M. Use of a long acting somatostatin analogue in controlling life threatening ileostomy diarrhoea. Br Med J (Clin Res Ed) 1984 Oct 20;289(6451):1027–1028. doi: 10.1136/bmj.289.6451.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Wright A. D., Hill D. M., Lowy C., Fraser T. R. Mortality in acromegaly. Q J Med. 1970 Jan;39(153):1–16. [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES